TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00636311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide, Gemcitabine, Vinorelbine
Description: Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib + IGEV
Description: Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
Study: NCT03786523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Study: NCT01210261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compumedics Somnilink SPAP - Auto-titrating CPAP
Description: Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resmed Autoset S8 - Auto-titrating CPAP
Description: Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment.
Study: NCT00632437

Intervention type: PROCEDURE
Intervention: Speckle-Contrast Imaging
Description: Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
Study: NCT02580643

Intervention type: BIOLOGICAL
Intervention: APS
Description: intra-articular injection
Study: NCT00294515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg orally daily for up to 100 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: 900 mg orally daily for up to 200 days
Study: NCT00324675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg tablets, bid, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets per day
Study: NCT03553680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused CBT
Description: 10 CBT Sessions to improve emotional regulation and emotional intelligence.
Study: NCT00836420

Intervention type: PROCEDURE
Intervention: no intervention
Description: the value of the clinical use of microdialysis monitoring of the brain
Study: NCT00802698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electric stimulation
Description: central artery occlusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal stimulation
Description: new waveform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcorneal electric stimulation
Description: Novel waveform central artery occlusion
Study: NCT00729079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP
Description: 1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP
Description: 1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use
Study: NCT01941719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced foot care education
Description: In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Foot Care Education
Description: At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams.
Study: NCT03614637

Intervention type: OTHER
Intervention: Cannabis use abstinence for 11 weeks
Description: Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
Study: NCT04001231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once-Weekly Suspension
Description: A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
Study: NCT00638781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 62.5 µg/kg BW
Study: NCT02486718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Study: NCT03736863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+ SHR-1210（Camrelizumab）
Description: Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+ SHR-1210（Camrelizumab）
Description: Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib+ SHR-1316（Adebrelimab）
Description: Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316（Adebrelimab）+SHR-A2009
Description: SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
Study: NCT03280719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Radiotherapy
Description: Prone positioning for regional nodal irradiation using the crawl breast couch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Radiotherapy
Description: Prone positioning for regional nodal irradiation using the crawl breast couch.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Acceleration
Description: Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Acceleration
Description: Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supine Radiotherapy
Description: Supine positioning for regional nodal irradiation using breastboard.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supine Radiotherapy
Description: Supine positioning for regional nodal irradiation using breastboard.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
Study: NCT00638781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 90 µg/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 125 µg/kg BW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04161625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital exercise program with support
Description: The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)
Study: NCT01240226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose
Study: NCT03280719

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionation
Description: Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
Study: NCT04191538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conditioning electrical stimulation
Description: Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative electrical stimulation
Description: Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No electrical stimulation
Description: Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
Study: NCT04531085

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operative treatment
Description: Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Long arm cast
Description: cast immobilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long arm cast
Description: cast immobilization
Study: NCT01838395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: IV (intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: SC (subcutaneous injection)
Study: NCT01240226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Oral repeating dose
Study: NCT01412697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake in rural youth
Description: A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
Study: NCT05070923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyLifetime
Description: HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
Study: NCT04077073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReIn-Hand
Description: ReIn-Hand assists the hand opening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReIn-Hand
Description: ReIn-Hand assists the hand opening

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot
Description: Robot supports the shoulder load
Study: NCT02167490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: sentinel node biopsy
Description: Sentinel node biopsy policy
Study: NCT04069689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPX-100 (Clemizole Hydrochloride)
Description: EPX-100 (Clemizole Hydrochloride)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo to match EPX-100
Study: NCT00496522

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proton Beam Therapy
Description: A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
Study: NCT03474588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment (ST) PLUS web-based CBT4CBT
Description: Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (ST)
Description: ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
Study: NCT04142606

Intervention type: OTHER
Intervention: fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)

Intervention type: OTHER
Intervention: fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)

Intervention type: OTHER
Intervention: fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)

Intervention type: OTHER
Intervention: fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
Study: NCT01240226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Oral repeating dose
Study: NCT02979392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)
Description: TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
Study: NCT03940352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBG453
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet
Study: NCT00292721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: celecoxib: loading and maintenance for 6 months
Study: NCT01553331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dissection of gallbladder in laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dissection of gallbladder in laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
Study: NCT03430531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
Study: NCT01435616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study: NCT04483505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination, Rogaratinib + palbociclib + fulvestrant
Description: Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression.
Study: NCT03451682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: procyanidine
Description: Natural antioxidant
Study: NCT00968227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: Transfusion of 1 unit of packed red blood cells over 1 hour.
Study: NCT01462123

Intervention type: OTHER
Intervention: endoscopic assessment of colonic polyps
Study: NCT03891693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux and SUPERA® stent
Description: Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
Study: NCT04648644

Intervention type: OTHER
Intervention: Application of ERAS protocol
Description: Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
Study: NCT04051736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Polio Vaccine
Description: Inactivated Polio Vaccine at age of 2,3,4 months old, respectively

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine
Description: Inactivated Polio Vaccine at age of 2,3,4 months old, respectively